Search results for "pathologic myopia"

showing 4 items of 4 documents

Update and guidance on management of myopia : European Society of Ophthalmology in cooperation with International Myopia Institute

2021

The prevalence of myopia is increasing extensively worldwide. The number of people with myopia in 2020 is predicted to be 2.6 billion globally, which is expected to rise up to 4.9 billion by 2050, unless preventive actions and interventions are taken. The number of individuals with high myopia is also increasing substantially and pathological myopia is predicted to become the most common cause of irreversible vision impairment and blindness worldwide and also in Europe. These prevalence estimates indicate the importance of reducing the burden of myopia by means of myopia control interventions to prevent myopia onset and to slow down myopia progression. Due to the urgency of the situation, t…

0301 basic medicinemedicine.medical_specialtygenetic structuresmedicine.medical_treatmentatropinePsychological interventionReviewsorthokeratologylikinäköisyyspreventive medicineehkäisevä lääketiede03 medical and health sciences0302 clinical medicineOphthalmologynäkövammatEpidemiologyMyopiaPrevalenceMedicineHumansmyopiaPreventive healthcareBlindnessbusiness.industrypathologic myopiaPathological myopiaOrthokeratologyHigh myopiaTreatment optionsGeneral Medicinemedicine.diseasetime spent outdoorsmyopia reduction interventionsMyopia Degenerative/epidemiologyeye diseasesOphthalmology030104 developmental biologyMyopia Degenerativesilmätaudit030221 ophthalmology & optometryDisease Progressionsense organsbusinessOrthokeratologic Proceduresblindnesssokeus
researchProduct

Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study.

2006

Purpose: To assess the safety and effectiveness of photodynamic therapy (PDT) with verteporfin for subfoveal choroidal neovascularization (CNV) secondary to pathologic myopia (PM). Methods: Sixty-two patients (62 eyes) with PM underwent PDT according to the guidelines of the Verteporfin in Photodynamic Therapy Study. Clinical evaluations performed at all study visits included measurement of best-corrected Snellen visual acuity, slit-lamp biomicroscopy, and fundus fluorescein angiography. Patients were followed up at 1 month and 3 months after treatment and thereafter at 3-month intervals. Results: The final visual acuity of the study patients, after a median follow-up of 31 months, improved…

AdultMaleRefractive errormedicine.medical_specialtyFovea CentralisVisual acuityPorphyrinsgenetic structuresmedicine.medical_treatmentVisual AcuityPhotodynamic therapyOphthalmologyPathologic myopiamedicineHumansProspective StudiesFluorescein AngiographyDioptreAgedAged 80 and overPhotosensitizing Agentsbusiness.industryVerteporfinGeneral MedicineMiddle Agedmedicine.diseaseVerteporfineye diseasesChoroidal NeovascularizationOphthalmologyLong term learningChoroidal neovascularizationPhotochemotherapyMyopia DegenerativeFemalesense organsmedicine.symptombusinessmyopia subfoveal choroidal neovascularization photodynamic therapy verteporfin.medicine.drugFollow-Up StudiesRetina (Philadelphia, Pa.)
researchProduct

Assessment of intravitreal anti-VEGF drugs and dexamethasone for retinal diseases in real world setting: A multi-centre prospective study from Southe…

2022

Describe drug utilisation and clinical outcomes of intravitreal anti-VEGF drug and dexamethasone use in the real-world setting in Southern Italy using data from multi-centre study of retinal disease. Clinical data of retinal disease patients treated with anti-VEGF drugs and dexamethasone implant in 6 out-patient ophthalmology centres from Southern Italy were collected by means of an electronic case report form. Patients receiving at least one intravitreal injection/implant of the study drugs were followed for up to two years and described in terms of demographics and clinical characteristics. Drug utilisation patterns were described. A sign-rank test was used to compare clinical data on vi…

MaleVascular Endothelial Growth Factor Agenetic structuresPharmacology &ltPHARMACOLOGY diabetic macular edema &ltbiostatisticsAngiogenesis InhibitorsDexamethasoneMacular DegenerationCATARACTRetinal DiseasesRanibizumabRetinal Vein OcclusionHumansProspective StudiesRETINAAgedAged 80 and overPharmacologySettore MED/30 - Malattie Apparato Visivopathologic myopiaGeneral MedicineMiddle AgedBevacizumabOphthalmologyLENSRETINA epidemiology / biostatistics pathologic myopia retina - medical therapies &ltIntravitreal InjectionsPharmacology diabetic macular edema RETINA epidemiology biostatisticsLENSCATARACTpathologic myopiaFemaleepidemiologydiabetic macular edemaEuropean Journal of Ophthalmology
researchProduct

IMI Prevention of Myopia and Its Progression

2021

The prevalence of myopia has markedly increased in East and Southeast Asia, and pathologic consequences of myopia, including myopic maculopathy and high myopia-associated optic neuropathy, are now some of the most common causes of irreversible blindness. Hence, strategies are warranted to reduce the prevalence of myopia and the progression to high myopia because this is the main modifiable risk factor for pathologic myopia. On the basis of published population-based and interventional studies, an important strategy to reduce the development of myopia is encouraging schoolchildren to spend more time outdoors. As compared with other measures, spending more time outdoors is the safest strategy…

ulkoilugenetic structuresContact Lensesmedicine.medical_treatmenttaittovirheetehkäisyatropinePopulationVisual impairmentlikinäköisyysorthokeratologyGlobal HealthRefraction Ocularmyopia-associated optic neuropathyOptic neuropathy03 medical and health sciences0302 clinical medicineMyopiaPrevalencemedicineHumansRisk factorhigh myopiaeducationeducation.field_of_studySpecial Issuebusiness.industrypathologic myopiamyopic macular degenerationOrthokeratologyAccommodation Ocularpiilolasitmedicine.diseaseeye diseasesAmplitude of accommodationEyeglassesDisease Progression030221 ophthalmology & optometryOptometryMaculopathysense organsmedicine.symptombusinessAccommodation030217 neurology & neurosurgeryInvestigative Opthalmology & Visual Science
researchProduct